Gain Therapeutics Inc (GANX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $46.31M
Last updated: Nov 17, 2026 at 4:42 PM ET
Gain Therapeutics Inc (GANX) Statistics
Gain Therapeutics (GANX) has a market cap of $46.31M and an enterprise value of $34.92M. Its share count is up 25.07% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 24.59% below the market cap, as cash exceeds debt.
| Market Cap | $46.31M |
|---|---|
| Enterprise Value | $34.92M |
| Latest price (Nov 17, 2026) | $1.18 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 5.1x |
|---|---|
| P/TBV Ratio | 5.1x |
Price Statistics
The stock is down 58.30% over 52 weeks and trades 18.06% below its 50-day average.
| Beta (1Y) | 1.64 |
|---|---|
| 52-Week Change | -58.30% |
| 1-Month Change | -5.60% |
| 3-Month Change | -43.00% |
| 6-Month Change | -25.79% |
| 5-Year Change | -83.76% |
| Total Return (1Y) | -58.30% |
| Total Return (3Y CAGR) | -24.11% |
| Total Return (5Y CAGR) | -33.05% |
| Return vs SPY (1Y) | -70.16% |
| Max Drawdown (1Y) | -77.51% |
| Max Drawdown (3Y) | -81.43% |
| Sharpe Ratio (1Y) | -0.80 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $1.44 |
| 200-Day Average | $1.81 |
| 52-Week Range | $0.94 to $4.34 |
| RSI (14 Days) | 48.3 |
| Average Volume (20 Days) | 729.92K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.36x current liabilities, and total debt is 0.03x shareholder equity.
| Current Ratio | 5.36x |
|---|---|
| Quick Ratio | 5.36x |
| Debt / Equity | 0.03x |
Returns and Efficiency
Return on invested capital is -170.49% and return on equity is -177.15% over the last 12 months.
| Return on Equity (ROE) | -177.15% |
|---|---|
| Return on Assets (ROA) | -135.90% |
| Return on Invested Capital (ROIC) | -170.49% |
| ROA (5Y Average) | -97.00% |
Scores
GANX has a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 4 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | $4.87M |
| Operating Income | -$17.70M |
| Pretax Income | -$17.55M |
| Net Income | -$17.98M |
| Reported EPS (TTM) | -$0.42 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 76.72% of the $13.23M in total assets.
| Cash and Equivalents | $11.70M |
|---|---|
| Total Debt | $308.71K |
| Net Cash | $11.39M |
| Net Cash Per Share | $0.26 |
| Working Capital | $10.33M |
| Shareholder Equity | $10.15M |
| Book Value Per Share | $0.23 |
| Tangible Book Value | $10.08M |
| Tangible Book Per Share | $0.23 |
| Total Assets | $13.23M |
| Total Liabilities | $3.08M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$17.07M |
|---|---|
| FCF Per Share | -$0.39 |
| Depreciation and Amortization | $95.97K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -14.82% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -14.40% |
Dividends and Yields
GANX does not pay a dividend.
| Buyback Yield | -32.42% |
|---|---|
| Shareholder Yield | -32.42% |
Peer Position
Against 5 similar companies, GANX has the 5th highest ROIC.
ROICPeer median -95.44%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -66.45%
| ROIC | -170.49% vs -95.44% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -66.45% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About GANX
What is GANX's market cap?
Gain Therapeutics has a market cap of $46.31M. Its enterprise value, which adds debt and subtracts cash, is $34.92M.
How many shares of GANX are outstanding?
Gain Therapeutics has 43.77M shares outstanding. The count is up 25.07% from a year earlier.
Does GANX pay a dividend?
No. Gain Therapeutics does not pay a dividend.
How much debt does GANX have?
Gain Therapeutics has $308.71K of total debt and $11.70M of cash and equivalents, a net cash position of $11.39M.
GANX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors